Citi initiated coverage of Acadia Pharmaceuticals (ACAD) with a Buy rating and $33 price target The firm believes Nuplazid and Daybue adoption will continue to increase in the near term. Acadia shares are being over-penalized for Nuplazid sales despite the patent litigation being resolved, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Hold Rating Amid Pipeline Shifts and Product Focus
- Acadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche Bank
- ACADIA Pharmaceuticals: Growth Potential Despite Setbacks with Promising Pipeline and Core Business Expansion
- Video: Soleno Therapeutics stock rallies on competitor’s failed trial
- Micron reports Q4 beat, Instagram reports 3B MAUs: Morning Buzz